NIMBLE Study

The NIMBLE Study is looking at a possible new medicine for people with eosinophilic asthma (a type of sever asthma). The study will look at how safe the study drug is and whether it works for adults and adolescents with eosinophilic asthma.

You may be able to take part in this study if you:

  • Are 12 years of age or over

  • Have severe asthma that has been controlled with mepolizumab or benralizumab for at least 12 months.

What is the NIMBLE Study?

The NIMBLE Study has 3 parts.

Part 1

Checking if the Study is Right for You (Up to 10 Weeks)

Visit Lucida Clinical 1 or 2 times to check if you might be able to take part.

Part 2

While you are Taking the Study Medication (1 year)

Receive one of the following:

  • Study drug (2 injections) plus placebo (7 or 13 injections).

  • Your usual medicine (13 injections of mepolizumab OR 7 injections of benralizumab) plus placebo (2 injections).

Have 15 study visits (either at Lucida Clinical or at home) for test and to check your health.

Part 3

After you Stop Taking the Study Medication (4 Weeks)

Visit Lucida Clinical once for tests and to check your health.

NIMBLE Study Q & A

Why is the NIMBLE Study important?

In eosinophilic asthma, normal white blood cells called “eosinophils” are increased in number. This may cause inflammation of the airways, leading to severe asthma attacks. It is hoped that the study drug can reduce the number of eosinophils and, therefore, the number of asthma attacks.

The study drug is being developed as an additional therapy for people with eosinophilic asthma who are already taking their usual asthma controller medicines. It is hoped that receiving the study drug every 6 months (26 weeks) will control asthma symptoms, compared to medicines already used to treat the condition, such as mepolizumab and benralizumab, which are taken every 1 to 2 months. It is hoped that this may make asthma care feel less overwhelming.

What medication will I take?

During the study, you will have an equal chance of receiving one of the following combinations:

  • Study drug + placebo

  • Your current medicine (mepolizumab OR benralizumab) + placebo

The placebo looks the same as the study drug but has no actual medicine in it.

The study medications will be given to you as subcutaneous (under the skin) injections.

During the study, you will keep taking your usual inhaled corticosteroids and at least one other long-term control medicine.